Another step in preparing QRX003 for potential commercialization Quoin Pharmaceuticals (NASDAQ: QNRX) has received FDA conditional approval of QYLEKI™ as the proposed brand name for…
June 23, 2026
Eli Lilly’s (NYSE: LLY) newly launched oral weight loss drug continues to gain rapid traction with patients and physicians, racking up 5,612 prescriptions in the…
April 29, 2026
Chiesi Group to Acquire KalVista Pharmaceuticals for $1.9B, Adding First Oral HAE Treatment to Rare Disease Portfolio
KalVista Pharmaceuticals (Nasdaq: KALV) surged 38% Wednesday after Italy-based Chiesi Group announced it will acquire the company for $27.00 per share in cash — a…
April 27, 2026
Jazz Pharmaceuticals Scores FDA Priority Review for Ziihera Combinations in First-Line HER2+ Gastroesophageal Cancer
Jazz Pharmaceuticals (NASDAQ: JAZZ) is moving closer to a major label expansion after the FDA accepted and granted Priority Review to its supplemental Biologics License…
April 23, 2026
Cumberland Pharmaceuticals Surges 80% on $100M Apotex Deal, Pivots to Orphan Drug Pipeline
Cumberland Pharmaceuticals (Nasdaq: CPIX) exploded higher Thursday, jumping 80% after the Nashville-based specialty pharma company announced a transformative transaction that hands its branded pharmaceutical business…
PharmaTher Holdings Ltd. (OTCQB: PHRRF) is currently positioning its proprietary PharmaPatch™ and PatchPrint™ platforms to benefit from major U.S. regulatory catalysts. This strategic alignment for…
Chronic obstructive pulmonary disease affects nearly 400 million people globally and ranks as the third leading cause of death worldwide. Despite standard inhaled treatments, more…
Eli Lilly and Company (NYSE: LLY) officially introduced Foundayo (orforglipron) to the United States market. Following FDA approval on April 1, 2026, the company designed…
Eli Lilly and Company (NYSE: LLY) recently achieved a landmark regulatory success with the FDA approval of Foundayo (orforglipron). This new oral treatment provides a…
Kodiak Sciences Inc. (NASDAQ: KOD) shares jumped after the company reported positive clinical trial data for its investigational eye drug, reviving the story around its…
February 26, 2026
Prescription Pressures: Why GoodRX Shares Fell 12%
GoodRx Holdings, Inc. (NASDAQ: GDRX) shares plummeted 12% in after-hours trading following the release of its fourth-quarter and full-year 2025 financial results. While the company…
Silo Pharma, Inc. (NASDAQ: SILO) shares moved sharply higher after the company announced a $1 million share repurchase program, signaling management’s confidence in the company’s…